David Burrows ISHARES DOW JONES US MEDICAL DEV.(ETF) IHI-N BUY Apr 22, 2021

(A Top Pick Oct 16/18, Up 16%) It continues to work. Everything is going right with this one. It is not a defensive name and while he likes it, he would not have more than a few percent of it in the market.

He loves it. It was flat over the last quarter. He is sticking with it.

He likes medical devices a lot. The ETF looks good with reasonable MER. Once the rhetoric from the presidential campaign subsides, it’ll probably have more smooth sailing.

It's very nichy, though it offers good exposure to healthcare. It's a high-beta play on healthcare, biotech and medical devices. His main worry is uncertainty around the US election, namely Bernie Sanders. If he nationalizes medical care, then this ETF will suffer.

It specializes in medical devices and equipment. He has held this over a year and a half. He likes the diversification it offers. He is not sure which of the holdings are involved in manufacturing defibrillators.

This ETF has smashed it over the past 5 years. Medical devices are a hybrid of tech and healthcare, which he really likes. Problem is that market enthusiasm and growth are priced in here already (like the FAANGs). Take profits.

Likes medical devices and health area as society ages. Would buy during a correcting. US and Europe have good healthcare stocks.

Allan Tong’s Discover Picks IHI's MER is actually higher (at 0.39%) than the yield it pays (0.3%). Like the other names here, IHI trades at a low beta, 0.86 to be precise. So, if you're not buying this for income, what's the growth? Let's look at IHI's largest holdings. TMO offers diversity among lab testing, lab equipment and diagnostics and typically trades at a premium multiple. TMO was a hit in the Covid-testing days, but that stereotype has stuck with them. The company reported a strong quarter a month ago, but that didn't move the needle. TMO shares have been choppy but rangebound all year, but if Wall Street gets gospel on TMO, share should pop. The price target is 20% higher at $674. Read 3 Best U.S. Healthcare ETFs for our full analysis.